Investigational Approaches in RCC

Video

Available on iTunes Podcast

For High-Definition, Click

There is limited utility for an mTOR inhibitor in the frontline setting for patients with renal cell carcinoma (RCC), notes Sumanta Kumar Pal, MD. The phase II RECORD-3 study compared sunitinib followed by everolimus to sequential everolimus and sunitinib. Overall, the trial did not demonstrate that first-line everolimus was noninferior to first-line sunitinib.

In the high-risk population, an mTOR inhibitor could be effective, notes Pal. In this situation, he prefers to utilize temsirolimus versus everolimus. At this time, there remains a need for prospective clinical trial data assessing the efficacy of an mTOR inhibitor in the frontline setting for high-risk patients with RCC.

In addition to frontline mTOR inhibition, there is limited data on the efficacy of neoadjuvant and adjuvant treatment for RCC. Neoadjuvant therapy would ideally be used when there is potential for curing disease prior to its surgical removal, notes Saby George, MD. However, this approach remains largely theoretical. Future trials should focus on tumor shrinkage or the use of nephron-sparing approaches in the setting of neoadjuvant therapy, George suggests.

Related Videos
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Wenxin (Vincent) Xu, MD,
Wenxin (Vincent) Xu, MD
A panel of 4 experts on bladder cancer
A panel of 4 experts on bladder cancer
Wenxin (Vincent) Xu, MD
A panel of 5 experts on renal cell carcinoma
A panel of 5 experts on renal cell carcinoma
A panel of 4 experts on bladder cancer
A panel of 4 experts on bladder cancer